Notes | Project documents | Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428] | Guidance

Please note that following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during mid-February 2027 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately late April 2027.